RESUMO
Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy with a poor survival despite aggressive multiagent chemotherapy. The combination of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has been reported to induce remissions in patients with ATL. The purpose of this study was to evaluate the clinical response and toxicity following administration of a combination of IFNalpha-2b and AZT in patients with human T-cell lymphotropic virus type I (HTLV-I)-associated ATL. Eighteen patients with ATL (chronic. crisis, acute or lymphoma type) were treated with the combination of AZT (50 - 200 mg orally 5 times a day) and IFNalpha-2b (2.5 - 10 million units subcutaneously daily). Three patients had objective responses lasting more than one month. One patient had a clinical complete remission, lasting 21.6 months and two patients had partial remissions lasting 3.7 and 26.5 months. Six patients were not considered evaluable for response due to short and/or interrupted periods of treatment. Seventeen patients have died with a median survival time after initiation of therapy of 6 months. Neutropenia and thrombocytopenia were the dose limiting toxicities. In conclusion, the response rate in this study was lower than noted in the two previous published series. This may be due to the amount and type of prior treatment our patients had received.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Interferon-alfa/administração & dosagem , Leucemia-Linfoma de Células T do Adulto/tratamento farmacológico , Zidovudina/administração & dosagem , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidade , Intervalo Livre de Doença , Feminino , Humanos , Interferon alfa-2 , Interferon-alfa/toxicidade , Leucemia-Linfoma de Células T do Adulto/complicações , Leucemia-Linfoma de Células T do Adulto/mortalidade , Masculino , Dose Máxima Tolerável , Pessoa de Meia-Idade , Neutropenia/induzido quimicamente , Proteínas Recombinantes , Indução de Remissão , Testes Cutâneos , Trombocitopenia/induzido quimicamente , Resultado do Tratamento , Zidovudina/toxicidadeRESUMO
Stannous chloride (SnCl2) is a reducing agent largely employed in industry and in medical procedures. To evaluate its potential genotoxicity, several Escherichia coli strains were treated with SnCl2 and their survival rates determined. Results showed that the double mutant on specific genes for the repair of deoxyribonucleic acid damage was the most sensitive strain. Simultaneous near-UV illumination inhibited the lethal effect of SnCl2 in the wild type strain. Although the nature of the induced lesions are not known these results indicate the potential genotoxicity of SnCl2.